ArticleMolecular biology reports2026
Virulence modulation and biofilm inhibition of Streptococcus pyogenes by metabolites from endophytic fungi associated with Vanda tessellata.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndophytic fungi represent a valuable source of bioactive metabolites with potential applications in addressing antimicrobial resistance. Biofilm formation by Streptococcus pyogenes contributes to antibiotic tolerance and persistent infections, highlighting the need for alternative anti-virulence strategies. METHODS AND
resultsIn this study, endophytic fungi associated with the medicinal orchid Vanda tessellata were isolated and evaluated for their antimicrobial and antibiofilm activity against S. pyogenes using in vitro assays, microscopy, and viability analysis. Among the isolates, Nodulisporium verrucosum exhibited the strongest antibiofilm activity, achieving 90% inhibition at its minimum biofilm inhibitory concentration (MBIC) of 0.5 mg/mL, without affecting bacterial viability. Bioactivity-guided HR-LCMS analysis of the active extract revealed nine putative metabolites. Further computational ADMET profiling and molecular docking analyses identified tributyrin as a promising anti-virulence candidate, showing favorable pharmacokinetic properties and stable interactions with key biofilm-associated regulatory proteins of S. pyogenes. In addition, tributyrin demonstrated low cytotoxicity in mammalian cells.
conclusionThese findings demonstrate the antibiofilm activity observed at the MBIC, along with the identification of tributyrin as a multi-target interacting compound, highlights the potential of V. tessellata-associated endophytic fungi as a promising source of anti-virulence agents. Together, this work provides a strong foundation for future molecular validation and in vivo evaluation of fungal-derived antibiofilm strategies.
Indexed as
Identifiers
42363969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.